GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Raphael Pharmaceutical Inc (OTCPK:RAPH) » Definitions » 3-Year EPS without NRI Growth Rate

Raphael Pharmaceutical (Raphael Pharmaceutical) 3-Year EPS without NRI Growth Rate : -14.50% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Raphael Pharmaceutical 3-Year EPS without NRI Growth Rate?

Raphael Pharmaceutical's EPS without NRI for the three months ended in Mar. 2024 was $-0.03.

During the past 3 years, the average EPS without NRI Growth Rate was -14.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 4 years, the highest 3-Year average EPS without NRI Growth Rate of Raphael Pharmaceutical was -14.50% per year. The lowest was -14.50% per year. And the median was -14.50% per year.


Competitive Comparison of Raphael Pharmaceutical's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Raphael Pharmaceutical's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Raphael Pharmaceutical's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Raphael Pharmaceutical's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Raphael Pharmaceutical's 3-Year EPS without NRI Growth Rate falls into.



Raphael Pharmaceutical 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Raphael Pharmaceutical  (OTCPK:RAPH) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Raphael Pharmaceutical 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Raphael Pharmaceutical's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Raphael Pharmaceutical (Raphael Pharmaceutical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
4 Lui Paster, Tel Aviv-Jaffa, ISR, 6803605
Raphael Pharmaceutical Inc is a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD oil.
Executives
Joseph Press director 4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Shlomo Pilo director, 10 percent owner, officer: Chief Executive Officer 4 LUI PASTER, TEL AVIV L3 6803605
Hayon Igal Louria director, officer: Chief Technology Officer 4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Yehuda Eliya director 4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Robert B Catell director 62 OSBORNE ROAD, GARDEN CITY NY 11530
Elisha Yanay director C/O ADVANCED TECHNOLOGY ACQUISITION CORP, 14 A ACHIMEIR STREET, RAMAT GAN L3 52587
Yacov A Shamash director
Guy Ofir director, 10 percent owner, officer: President 40 BAZ STREET, KARMIEL L3 20100
Emanuel Cohen director, 10 percent owner, officer: Secretary Treasurer Director 51 BILU STREET, RA'ANANA L3 00000

Raphael Pharmaceutical (Raphael Pharmaceutical) Headlines

No Headlines